The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Liquid biopsy NGS improves treatment decision-making in NSCLC
Luis Raez, MD, Memorial Cancer Institute, Pembroke Pines, FL, provides an overview of liquid biopsy next-generation sequencing (NGS) techniques to guide treatment strategies for advanced non-small cell lung cancer (NSCLC). In a real-world cohort, plasma-based testing demonstrated faster turnaround, higher sample success rates, and strong concordance with tissue biopsy, while significantly reducing time to therapy initiation. These findings highlight how liquid biopsy can complement or, in some cases, substitute tissue testing, thereby supporting timely, personalized treatment decisions and improving clinical management in metastatic disease. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, we have another poster talking about that. Basically, we have close to 300 patients that we compare the standard of care NGS, no, genetic study in tissue with liquid biopsy NGS. The results show that in eight days as an average, we get the liquid results. So in 75% of the patients with metastatic lung cancer, they are when their sample arrived. We can make the decision about what’s the treatment...
Yeah, we have another poster talking about that. Basically, we have close to 300 patients that we compare the standard of care NGS, no, genetic study in tissue with liquid biopsy NGS. The results show that in eight days as an average, we get the liquid results. So in 75% of the patients with metastatic lung cancer, they are when their sample arrived. We can make the decision about what’s the treatment. 75% of the time, close to 80% of the time. For the other 25% of the patients, we need to wait the extra two weeks until the tissue NGS arrives. So that is what is so important. All over the world, even in America, it is not standard of care to order tissue and liquid at the same time. We promote that it needs to be done because that’s the way that we can accelerate onset of therapy in lung cancer patients that are already waiting and they get very upset when they have to wait three or four weeks for an NGS tissue result.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
